Progress in active-specific immunotherapy of brain malignancies

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA:Cancer statistics,2000. CA Cancel-J. Clin. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• FINE HA: The basis for current treatment recommenda-tions for malignant gliomas. J. Neurooncol. (1994) 20:111–120.
   PubMed Web of Science ®Google Scholar
• JANUS TJ, KYRITSIS AP, FORMAN AD, LEVIN VA: Biology and treatment of gliomas. Ann. Oncol. (1992) 3:423–433.
   PubMed Web of Science ®Google Scholar
• WINGER MJ, MACDONALD DR, CAIRNCROSS JG: Suprat-entorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. j Neurosurg. (1989) 71:487–493.
   Google Scholar
• MAHALEY MS, JR., METTLIN C, NATARAJAN N, LAWS ER, JR., PEACE BB: National survey of patterns of care for brain-tumor patients. J Neurosurg. (1989) 71:826–836.
   PubMed Web of Science ®Google Scholar
• BLACK KL, PIKUL BK: Gliomas - past, present and future. Clin. Neurosurg. (1999) 45:160–163.
   PubMedGoogle Scholar
• BLACK PM, MORIARTY T, ALEXANDER E et al: Develop-ment and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. Neurosurgery (1997) 41:831–842.
   PubMed Web of Science ®Google Scholar
• WIRTZ CR, BONSANTO MM, KNAUTH M et al.: Intraop-erative magnetic resonance imaging to update interac-tive navigation in neurosurgery: method and preliminary experience. Comput. Aided Surg. (1997) 2:172–179.
   PubMedGoogle Scholar
• SALCMAN M: Glioblastoma multiforme. Am. J. Med. Sci.(1980) 279:84–94.
   PubMed Web of Science ®Google Scholar
• SHAPIRO W, GREEN S, BURGER P et al: A randomisedtrial of interstitial radiotherapy (IRT) boost for treatment of newly diagnosed malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroma, malignant mixed glioma): BTCG study 8701. Neurology (1994) 44 (Suppl. 2):263. Abstract.
   Google Scholar
• SHRIEVE DC, ALEXANDER E, BLACK PM et al: Treatmentof patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J. Neurosurg. (1999) 90:72–77.
   PubMed Web of Science ®Google Scholar
• BREM H, PIANTADOSI S, BURGER PC et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet (1995) 345:1008–1012.
   PubMed Web of Science ®Google Scholar
• RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. (1997) 3:1354–1361.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, GOMEZ-MANZANO C, BALAGUE C et al: Gene therapy for gliomas: molecular targets, adenoviral vectors and oncolytic adenoviruses. Exp. Cell Res. (1999) 252:1–12.
   PubMed Web of Science ®Google Scholar
• DAVIS FG, FREELS S, GRUTSCH J, BARLAS S, BREM S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology and end results (SEER) data, 1973-1991. Neurosurg. (1998) 88:1–10.
   Web of Science ®Google Scholar
• KRIKORIAN J, PORTLOCK C, COONEY D, ROSENBERG S: Spontaneous regression of non-Hodgkin's lymphoma. A report of nine cases. Cancer (1980) 46:2093–2099.
   Google Scholar
• KIM TY, VON ESCHENBACH AC, FILACCIO MD et al: Clonal analysis of lymphocytes from tumor, periph-eral blood and nontumorous kidney in primary renal cell carcinoma. Cancer Res. (1990) 50:5263–5268.
   PubMed Web of Science ®Google Scholar
• DEVITA V, JR.: Principles of chemotherapy. In: Cancer Principles & Practice of Oncology. DeVita V, Jr., Hellman S, Rosenberg S (Eds.), Lippincott, Philadelphia, PA, USA (1997)276.
   Google Scholar
• BARKER CF, BILLINGHAM RE: Immunologically privileged sites. Adv. Immunol. (1977) 25:1–54.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. Clin. Oncol (1989) 7:1701–1709.
   Web of Science ®Google Scholar
• KALMAN B, LUBLIN FD: Immunopathogenic mechanisms in experimental allergic encephalomye-litis. Curr. Opin. Neurol. Neurosurg. (1993) 6:182–188.
   PubMedGoogle Scholar
• CSERR HF, KNOPF PM: Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today (1992) 13:507–512.
   PubMedGoogle Scholar
• ULVESTAD E, WILLIAMS K, BJERKVIG R, TIEKOTTER K, ANTEL J, MATRE R: Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc. Biol. (1994) 56:732–740.
   PubMed Web of Science ®Google Scholar
• •Characterisation of microglia as a component of the CNS that possesses antigen-presenting capacity.
   Google Scholar
• ALOISI F, RIA F, COLUMBA-CABEZAS S, HESS H, PENNA G, ADORINI L: Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1 /Th2 cell restimulation. Eur.J. Iminunol. (1999) 29:2705–2714.
   PubMed Web of Science ®Google Scholar
• DIX AR, BROOKS WH, ROSZMAN TL, MORFORD LA: Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunother. (1999) 100:216–232.
   PubMed Web of Science ®Google Scholar
• GROSEN EA, GRANGER GA, GATANAGA M et al.: Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol. Oncol. (1993) 50:68–77.
   PubMed Web of Science ®Google Scholar
• NAGANUMA H, SASAKI A SATOH E et al.: Inhibition of tumor necrosis factor alpha and beta secretion by lymphokine activated killer cells by transforming growth factor-P. Jpn. J. Cancer Res. (1994) 85:952–957.
   Google Scholar
• HISHII M, NITTA T, ISHIDA H et al.: Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery (1995) 37:1160–1166.
   PubMed Web of Science ®Google Scholar
• GRATAS C, TOHMA Y, VAN MEIR EG et al: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. (1997) 7:863–869.
   PubMed Web of Science ®Google Scholar
• SAWAMURA Y, DISERENS AC, DE TRIBOLET N: In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J. Neurooncol. (1990) 9:125–130.
   PubMed Web of Science ®Google Scholar
• VAN MEIR E, CESKA M, EFFENBERGER F et al.: Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res. (1992) 52:4297–4305.
   PubMed Web of Science ®Google Scholar
• VAN MEIR E, SAWAMURA Y, DISERENS AC, HAMOU MF,DE TRIBOLET N: Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. (1990) 50:6683–6688.
   PubMed Web of Science ®Google Scholar
• IWASAKI K, ROGERS LR, ESTES ML, BARNA BP: Modula-tion of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma. Neurosurgery (1993) 33:489–493.
   PubMed Web of Science ®Google Scholar
• KONDO S, YIN D, TAKEUCHI J et al.: Tumour necrosis factor-a induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis. Br. J. Cancer (1994) 69:627–632.
   PubMed Web of Science ®Google Scholar
• MERCHANT RE, ELLISON MD, YOUNG HF: Irnmuno-therapy for malignant glioma using human recombi-n ant in terleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J. Neurooncol. (1990) 8:173–188.
   PubMed Web of Science ®Google Scholar
• STUBEN G, BAMBERG M, BUDACH W, STUSCHKE M, NIEDERLE N: Tumor necrosis factor-a new therapeutic approach. Preclinical studies in nude mice. Strahlen-ther. Onkol. (1989) 165:554–556.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MUUL LM et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl. J. Med. (1987) 316:889–897.
   PubMed Web of Science ®Google Scholar
• JEREB B, PETRIC-GRABNAR G, KLUN B, LAMOVEC J, SKRBEC M, SOOS E: Addition of IFN-a to treatment of malignant brain tumors. Acta Oncol. (1994) 33:651–654.
   PubMed Web of Science ®Google Scholar
• YUNG WK, PRADOS M, LEVIN VA et al.: Intravenous recombinant interferon 13 in patients with recurrent malignant gliomas: a Phase VII study. J Clin. Oncol (1991) 9:1945–1949.
   PubMed Web of Science ®Google Scholar
• FARKKILA M, JAASKELAINEN J, KALLIO M et al.: Random-ised, controlled study of intratumoral recombinant 7-interferon treatment in newly diagnosed glioblas-toma. Br. J. Cancer (1994) 70:138–141.
   PubMed Web of Science ®Google Scholar
• YOSHIDA J, WAKABAYASHI T, MIZUNO M et al: Clinicaleffect of intra-arterial tumor necrosis factor-a for malignant glioma. j Neurosurg. (1992) 77:78–83.
   PubMed Web of Science ®Google Scholar
• MERCHANT RE, MCVICAR DW, MERCHANT LH, YOUNGHF: Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombi-nant interleukin-2 alone or in combination with systemic interferon-a. Results of a Phase I clinical trial. Neurooncol. (1992) 12:75–83.
   Google Scholar
• LEE Y, BULLARD DE, HUMPHREY PA et al.: Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 8106. Cancer Res. (1988) 48:2904–2910.
   PubMed Web of Science ®Google Scholar
• CHEUNG NK, LAZARUS H, MIRALDI FD et al.: Ganglio side GD2 specific monoclonal antibody 3F8: a Phase I study in patients with neuroblastoma and malignant melanoma. J Clin. Oncol. (1987) 5:1430–1440.
   PubMed Web of Science ®Google Scholar
• WERNER MH, HUMPHREY PA, BIGNER DD, BIGNER SH:Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGFreceptor on four glioma cell lines. Acta Neuropathol (1988) 77:196–201.
   PubMed Web of Science ®Google Scholar
• BIGNER DD, BROWN M, COLEMAN RE et al.: Phase Istudies of treatment of malignant gliomas and neoplastic meningitis with 1 31I-radiolabeled monoclonal antibodies anti-tenascin 81 C6 and anti-chondroitin proteoglycan sulfate Mel-1 4 F(ab')2 - a preliminary report. J Neurooncol. (1995) 24:109–122.
   PubMed Web of Science ®Google Scholar
• BIGNER DD, BROWN MT, FRIEDMAN AH et al: Iodine-131-labeled antitenascin monoclonal antibody 81 C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin. Oncol. (1998) 16:2202–2212.
   PubMed Web of Science ®Google Scholar
• RIVA P, FRANCESCHI G, ARISTA A et al.: local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer (1997) 80:2733–2742.
   PubMed Web of Science ®Google Scholar
• TZENG JJ, BARTH RF, CLENDENON NR, GORDON WA: Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. (1990) 50:4338–4343.
   PubMed Web of Science ®Google Scholar
• BARBA D, SARIS SC, HOLDER C, ROSENBERG SA, OLDFIELD EH: Intratumor al LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. (1989) 70:175–182.
   PubMed Web of Science ®Google Scholar
• LILLEHEI KO, MITCHELL DH, JOHNSON SD, MCCLEARYEL, KRUSE CA: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery (1991) 2 8:16–23.
   Google Scholar
• SANKHLA SK, NADKARNI JS, BHAGWATI SN: Adoptiveimmunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol. (1996) 27:133–140.
   PubMed Web of Science ®Google Scholar
• HOLLADAY FP, HEITZ T, CHEN YL, CHIGA M, WOOD GW:Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery (1 99 2) 31:528–533.
   Google Scholar
• PLAUTZ GE, BARNETT GH, MILLER DW et al: Systemic T cell adoptive immunotherapy of malignant gliomas. Neurosurg. (1998) 89:42–51.
   Web of Science ®Google Scholar
• BLOOM HJ, PECKHAM MJ, RICHARDSON AE, ALEXANDER PA, PAYNE PM: Glioblastoma multiforme: a controlled trial to assess the value of specific active immuno-therapy in patients treated by radical surgery and radiotherapy. Br. J. Cancer (1973) 27:253–267.
   PubMed Web of Science ®Google Scholar
• MAHALEY MS, JR., BIGNER DD, DUDKA LF et al.: Irnmunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg. (1983) 59:201–207.
   Google Scholar
• SAMPSON JH, ARCHER GE, ASHLEY DM et al: Subcuta-neous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the 'immunolog-ically privileged' central nervous system. Proc. Nati Acad. Sci. USA (1996) 93:10399–10404.
   PubMed Web of Science ®Google Scholar
• JEAN WC, SPELLMAN SR, WALLENFRIEDMAN MA, HALL WA, LOW WC: Interleukin-1 2-based immunotherapy against rat 9L glioma. Neurosurgery (1998) 42:850–856.
   PubMed Web of Science ®Google Scholar
• WALLENFRIEDMAN MA, CONRAD JA, DELABARRE L et al.: Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg. (1999) 90:1064–1071.
   PubMed Web of Science ®Google Scholar
• URBAN JL, SCHREIBER H: Tumor antigens. Ann. Rev. Immuno. (1992) 10:617–644.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON P: Ganglioside vaccines with emphasis on GM2. Semin. Oncol. (1998) 25:636–645.
   PubMed Web of Science ®Google Scholar
• BOURDON MA, WIKSTRAND CJ, FURTHMAYR H, MATTHEWS TJ, BIGNER DD: Human glioma-mesenchymal ex tracellular matrix antigen defined by monoclonal antibody. Cancer Res. (1983) 43:2796–2805.
   PubMed Web of Science ®Google Scholar
• SCARCELLA DL, CHOW CW, GONZALES MF, ECONOMOU C, BRASSEUR F, ASHLEY DM: Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin. Cancer Res. (1999) 5:335–341.
   PubMed Web of Science ®Google Scholar
• CHI DD, MERCHANT RE, RAND R et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am. J Pathol. (1997) 1 5 0:2143–2152.
   Google Scholar
• KNIGHT SC, STAGG AJ: Antigen-presenting cell types. Curr. Opin. Immunol. (1993) 5:374–382.
   PubMed Web of Science ®Google Scholar
• MELLMAN I, TURLEY SJ, STEINMAN RM: Antigen processing for amateurs and professionals. Trends Cell Biol. (1998) 8:231–237.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The den dritic cell system and its role in immunogenicity. Ann. Rev. Immunol. (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• •One of the first comprehensive review articles on the dendritic cell system.
   Google Scholar
• INABA K, METLAY JP, CROWLEY MT, WITMER-PACK M, STEINMAN RM: Dendritic cells as antigen presenting cells in vivo. Int. Rev. Immunol. (1990) 6:197–206.
   PubMedGoogle Scholar
• MACKENSEN A, HERBST B, CHEN JL et al:Phase I study inmelanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Ini J Cancer (2000) 86:385–392.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al.: Infusion ofdendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate (1999) 38:73–78.
   PubMed Web of Science ®Google Scholar
• TJOA BA, SIMMONS SJ, BOWES VA et al.: Evaluation ofPhase I/D clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 36:39–44.
   PubMed Web of Science ®Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination ofpatients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. (1996) 2:52–58.
   PubMed Web of Science ®Google Scholar
• •The first paper to report the result of a clinical trial involving DC-based cancer vaccine.
   Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nature Med. (1998) 4:328–332.
   PubMed Web of Science ®Google Scholar
• KUGLER A, STUHLER G, WALDEN P et aL: Regression of human metastatic renal cell carcinoma after vaccina-tion with tumor cell-dendritic cell hybrids [see comments]. Nature Med. (2000) 6:332–336.
   PubMed Web of Science ®Google Scholar
• HOLTL L, RIESER C, PAPESH C et al: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urof (1999) 161:777–782.
   PubMed Web of Science ®Google Scholar
• FREUDENTHAL PS, STEINMAN RM: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl. Acad. Sci. USA (1990) 87:7698–7702.
   PubMed Web of Science ®Google Scholar
• BERNHARD H, DISIS ML, HEIMFELD S, HAND S, GRALOW JR, CHEEVER MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. (1995) 55:1099–1104.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, LANZAVECCHIA A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregu-lated by tumor necrosis factor a. J Exp. Med. (1994) 179:1109–1118.
   PubMed Web of Science ®Google Scholar
• TJOA B, ERICKSON S, BARREN R, 3RD et al: In vitropropagated dendritic cells from prostate cancer patients as a component of prostate cancer immuno-therapy. Prostate (1995) 27:63–69.
   PubMed Web of Science ®Google Scholar
• SIESJO P, VISSE E, SJOGREN HO: Cure of established,intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-y treatment. J. Immunother. Emphasis Tumour Immunol. (1996) 19:334–345.
   PubMed Web of Science ®Google Scholar
• •The first paper to report a DC vaccine study that targeted intracranial tumours.
   Google Scholar
• ASHLEY DM, FAIOLA B, NAIR S, HALE LP, BIGNER DD,GILBOA E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. (1997) 186:1177–1182.
   PubMed Web of Science ®Google Scholar
• OKADA H, TAHARA H, SHURIN MR eta].: Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int. J. Cancer (1998) 78:196–201.
   Google Scholar
• LIAU LM, BLACK KL, PRINS RM et al.: Treatment o f in tr ac-ranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. (1999) 90:1115–1124.
   PubMed Web of Science ®Google Scholar
• HEIMBERGER AB, CROTTY LE, ARCHER GE et al.: Bonemarrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J. Neuroimmunol. (2000) 103:16–25.
   PubMed Web of Science ®Google Scholar